# Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

> **NCT00435916** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 46 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** SGN-40

## Key facts

- **NCT ID:** NCT00435916
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435916, "Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00435916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*